Reply to thread

Semantics, but yes...I can, all those products that cost 100 to 150 million to get smacked by the FDA an never come to market.  For a company the size of Greer it doesn't need to be a Billion Dollar market.  That's Greer's biggest problem.  They lack transparency.  Just be honest.  Greer has leadership in Allergy Immunotherapy from an extract perspective.  Oralair is/was supposed to be the golden ticket into Specialty and PCPs with other products.  Oralair's SalesForce was supposed to show it was worthy of a partnership or bringing in another product backed by other investors if necessary.  STAGR has not done that unless you count a recent 50 million dollar line of credit and the recent Stanford deal. 


In the US there is only Grass right now, and HDM and possibly tree and even genetic testing for which patients will do well with respect to nut allergies is a few or more years off.  It's been said a million times...something needs to happen within months because there is no way this Sales Force lasts long enough for HDM or any other "Pipeline" product.  And seriously, ALK has their HDM drug studied and presented to the FDA already and we haven't even enrolled our final patients, despite the fact we have data and indications overseas.  It's pretty much an indictment on how the US affiliate is being run combined with just a lack of SLIT opportunity in the US.